⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439179 | 1.00 | — | — | |
| SCHEMBL7511925 | 1.00 | — | — | |
| SCHEMBL3439154 | 1.00 | — | — | |
| SCHEMBL141573 | 0.77 | — | — | |
| SCHEMBL3418272 | 0.75 | — | — | |
| SCHEMBL4325538 | 0.75 | — | — | |
| SCHEMBL4320800 | 0.75 | — | — | |
| SCHEMBL12189698 | 0.75 | — | — | |
| SCHEMBL8860014 | 0.74 | — | — | |
| SCHEMBL29220459 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103228142-A | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | UNIV CALIFORNIA | 2013-07-31 | — | — | CN | claimed |
| CN-107050456-B | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | 加利福尼亚大学董事会 | 2022-08-12 | — | — | CN | disclosed |
| CN-103228142-A | GABA agonists for the treatment of diseases associated with metabolic syndrome and GABA combinations for the treatment or prevention of type I diabetes | UNIV CALIFORNIA | 2013-07-31 | — | — | CN | disclosed |
| CN-101087614-A | New use of GABAbeta receptor agonists | ASTRAZENECA AB (SE) | 2007-12-12 | — | — | CN | disclosed |
| EP-1833487-A1 | NEW USE OF GABAB RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-20060160777-A1 | New use of GABAbeta receptor agonists | ASTRAZENECA AB (SE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006071185-A1 | NEW USE OF GABAB RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2006-07-06 | — | — | WO | disclosed |